A Phase II Study of Daratumumab in Patients with Recurrent or Persistent Waldenström Macroglobulinemia

Print

Full Title

PAC Protocol: A Phase 2 Study of Daratumumab in Patients with Relapsed or Refractory Waldenström Macroglobulinemia

Purpose

Daratumumab is approved for treating multiple myeloma that continues to grow despite prior therapy. In this study, researchers are assessing the safety and effectiveness of daratumumab in patients with a blood disorder called Waldenström macroglobulinemia (WM) that continues to grow despite prior treatment.

Daratumumab targets a protein called CD38, which is found in myeloma as well as WM cells, and causes cancer cell death. It is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have WM that has come back or continued to grow despite at least one prior regimen of treatment.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. M. Lia Palomba at 212-639-7186.

Protocol

18-350

Phase

II

Investigator

Co-Investigators